Loading...
Loading...
RNA| Name | Value |
|---|---|
| Revenues | 2.2M |
| Cost of Revenue | 1.1M |
| Gross Profit | 1.2M |
| Operating Expense | 59.8M |
| Operating I/L | -52.8M |
| Other Income/Expense | 5.2M |
| Interest Income | 5.5M |
| Pretax | -52.4M |
| Income Tax Expense | -5.2M |
| Net Income/Loss | -47.2M |
Avidity Biosciences, Inc. is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies. Their primary focus is on creating antibody oligonucleotide conjugates (AOC) to address serious diseases. The company's lead product candidates include AOC 1001 for myotonic dystrophy type 1, AOC 1044 for Duchenne Muscular Dystrophy, and AOC 1020 for facioscapulohumeral muscular dystrophy, all in the preclinical stage. Additionally, they offer Lumizyme therapy for Pompe diseases, showcasing their commitment to developing innovative treatments for rare and debilitating conditions.
